Published Technical Disclosure Archive

RNA-based Solutions for Diverse Industries

Publication ID: 24-11857681_0002_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “RNA-based Solutions for Diverse Industries,” Published Technical Disclosure No. 24-11857681_0002_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857681_0002_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,681.

Summary of the Inventive Concept

This inventive concept leverages lipid-formulated RNA encoding immunogens to address unmet needs in personalized nutrition, environmental monitoring, bioterrorism detection, crop optimization, and neurological disorder treatment.

Background and Problem Solved

The original patent disclosed lipid formulations with RNA encoding immunogens for immunization. However, these formulations had limited applications. The new claims address this limitation by applying the core technology to diverse industries, solving problems such as tailored nutrition, pollution monitoring, bioterrorism detection, crop yield optimization, and neurological disorder treatment.

Detailed Description of the Inventive Concept

The inventive concept comprises RNA molecules encoding immunogens formulated with lipid particles, which are administered to stimulate an immune response tailored to specific needs. In personalized nutrition, the RNA molecules are used to stimulate an immune response that addresses individual health needs. In environmental monitoring, the RNA molecules detect changes in immune responses of aquatic organisms to determine pollution levels. In bioterrorism detection, the RNA molecules trigger an immune response specific to bioterrorism agents. In crop optimization, the RNA molecules stimulate plant immune responses to enhance resistance to disease and pests. In neurological disorders, the RNA molecules stimulate an immune response in the brain to treat disorders.

Novelty and Inventive Step

The new claims introduce a novel application of lipid-formulated RNA encoding immunogens to diverse industries, which is non-obvious and unforeseen from the original patent. The inventive step lies in recognizing the potential of this technology to solve problems beyond immunization.

Alternative Embodiments and Variations

Alternative embodiments may include different types of RNA molecules, lipid particles, or delivery systems. Variations may involve using different immunogens or targeting different industries, such as cosmetics or veterinary medicine.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in various industries, including healthcare, agriculture, environmental monitoring, and biodefense. The market size for these applications is substantial, with potential for growth and expansion into new areas.

CPC Classifications

SectionClassGroup
A A61 A61K9/127
A A61 A61K9/1272
A A61 A61K31/7088
A A61 A61K39/00
A A61 A61K39/12
C C12 C12N15/86
A A61 A61K39/39
A A61 A61K2039/53
A A61 A61K2039/55555
C C12 C12N2710/16134
C C12 C12N2760/18534
C C12 C12N2770/36134

Field of Art

Biotechnology and pharmaceutical sciences, specifically non-viral RNA delivery systems for immunological applications, with expertise in lipid nanoparticle formulations, RNA molecule design, and immunogen encoding

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in molecular biology or bioengineering, experienced in RNA delivery technologies, familiar with lipid nanoparticle formulations, and understanding of immunological response mechanisms across biological systems

Obviousness Rationale

A PHOSITA would recognize that the core RNA lipid delivery technology from the source patent provides a versatile platform that can be readily adapted to multiple application domains. The fundamental principles of RNA encoding, lipid particle formulation, and immune response stimulation are transferable across different contexts. The PTD demonstrates predictable extensions of the original technology by applying known RNA delivery mechanisms to solve problems in diverse industries.

Obvious Combinations & Variations

Source Patent Element
RNA molecules encoding immunogens formulated with lipid particles
PTD Variation
Applying RNA immunogen technology to personalized nutrition and environmental monitoring
Obviousness Reasoning
A PHOSITA would recognize that immune response stimulation is a predictable technique that can be adapted to different biological contexts using known RNA delivery principles
Source Patent Element
Lipid particle composition with PEG-conjugated lipids
PTD Variation
Modifying lipid particle delivery for crop optimization and neurological disorder treatments
Obviousness Reasoning
The fundamental lipid nanoparticle design is a known technique that can be systematically adapted to different target tissues and delivery requirements
Source Patent Element
RNA molecules with specific cap structures and 2'-methylated ribose
PTD Variation
Utilizing identical RNA molecular design principles across bioterrorism detection and other specialized applications
Obviousness Reasoning
RNA molecular engineering techniques are transferable across different technological domains, representing a predictable scientific approach
Source Patent Element
Immunogen encoding for viral targets like EBV and CMV
PTD Variation
Expanding immunogen encoding to plant immune responses and neurological system targeting
Obviousness Reasoning
Immunogen design principles are generalizable, and a PHOSITA would recognize the potential for cross-domain application of RNA encoding technologies
Source Patent Element
Non-viral RNA delivery for immunization
PTD Variation
Extending delivery mechanisms to diverse industries beyond traditional medical applications
Obviousness Reasoning
The fundamental RNA delivery technology represents a flexible platform with predictable adaptability to multiple technological domains
35 U.S.C. § 103 Summary: Based on US Patent 11857681's disclosure of lipid-formulated RNA immunogen delivery, the present publication demonstrates that a person of ordinary skill in the art would find the disclosed variations obvious and predictable extensions of existing RNA delivery technologies, thereby establishing prior art that would render subsequent similar claims obvious and non-patentable.

Original Patent Information

Patent NumberUS 11,857,681
TitleLipid formulations with RNA encoding immunogens
Assignee(s)GlaxoSmith Kline Biologicals S.A.